Last updated on December 2017

A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma (NAVIGATOR)

Brief description of study

The purpose of this global study is to confirm the efficacy and safety of 210 mg dose of tezepelumab administered subcutaneously SC every 4 weeks (Q4W) in adults and adolescents (12 years of age and older) with a history of asthma exacerbations and severe, uncontrolled asthma receiving medium or high dose inhaled corticosteroid (ICS) plus at least one additional asthma controller medication with or without oral corticosteroids (OCS). The study will evaluate the incidence of asthma exacerbations and other efficacy parameters such as lung function, asthma control and quality of life as well as a safety evaluation to further characterize the benefit-risk profile of the drug.

Clinical Study Identifier: TX155184

Contact Investigators or Research Sites near you

Start Over

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.